Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations

Losses of 5–10% or more of initial body weight are associated with improvements in obesity-related comorbidities. However, attaining and sustaining this level of weight loss is challenging. The novel anti-obesity medication semaglutide 2.4 mg injected subcutaneously once weekly as an adjunct to a re...

Descripción completa

Detalles Bibliográficos
Autores principales: Chao, Ariana M, Tronieri, Jena Shaw, Amaro, Anastassia, Wadden, Thomas A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807016/
https://www.ncbi.nlm.nih.gov/pubmed/36601368
http://dx.doi.org/10.2147/DDDT.S365416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807016/
https://www.ncbi.nlm.nih.gov/pubmed/36601368
http://dx.doi.org/10.2147/DDDT.S365416

Ejemplares similares